Skip to main content
SpringerLink
Log in

Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2

  • Published:
Biotherapy

Abstract

We have investigated biological properties of an immune complex of recombinant interleukin-2 (rIL-2) and a monoclonal antibody against rIL-2 in mice for induction of killer cells and for anti-tumor activity. We have also examined the clearance of subcutaneously-injected immune complex in mice and compared it with that of rIL-2 alone. Plasma rIL-2 levels were sustained longer in mice given the immune complex than in mice given rIL-2 alone at a dose of 10μg/mouse, and they were detectable even at 24 hours after the administration of the immune complex, while they fell to undetectable levels by 6 hours after the administration of rIL-2 alone. A more significant portion of rIL-2 was detected in lymph nodes after subcutaneous injection of the immune complex than that of rIL-2 alone. Splenic lymphocytes from mice given the immune complex demonstrated a higher killer cell activity against YAC-1 cells than those from mice given rIL-2 alone. The immune complex also exerted more significant anti-tumor effect in a dose-dependent manner in Meth-A fibrosarcoma-bearing mice than rIL-2 alone. Our results indicate that immunocomplexing of rIL-2 with an antibody against rIL-2 provides a useful tool as the drug delivery system for cancer therapy using rIL-2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

rIL-2:

recombinant interleukin-2

NK:

natural killer

MoAb:

Monoclonal antibody

References

  1. Smith KA. Interleukin-2: inception, impact, and implication. Science 1988; 240: 1169–76.

    PubMed  Google Scholar 

  2. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM. Observations on the systemic administration of autologuous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313: 1485–92.

    PubMed  Google Scholar 

  3. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. JAMA 1986; 256: 3117–24.

    PubMed  Google Scholar 

  4. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee EE, Rubin JT, Seipp CA, Simpson CG, White DE. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 1987; 316: 889–97.

    PubMed  Google Scholar 

  5. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldman RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898–905.

    PubMed  Google Scholar 

  6. Damle NK, Doyle LV. IL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayer. Implication for vascular leak syndrome. J Immunol 1989; 142: 2660–9.

    PubMed  Google Scholar 

  7. Muhlradt PF, Optiz HG. Clearance of interleukin-2 from the blood of normal and Tcell-depleted mice. Eur J Immunol 1982; 12: 983–85.

    PubMed  Google Scholar 

  8. Donohue JH, Rosenberg SA. The fate of interleukin-2 afterin vivo administration. J Immunol 1983; 130: 2203–8.

    PubMed  Google Scholar 

  9. Fujiwara T, Sakagami K, Matsuoko J, Shiozaki S, Fujioka K, Takada Y, Uchida S, Onoda T, Orita K. Augmentation of anti-tumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 minipellet. Biotherapy 1991; 3: 203–9.

    PubMed  Google Scholar 

  10. Nandini VK, Michael JK, Walter JL. Chemical modification of recombinant interleukin 2 by polyethylene glycol increase its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci USA 1987; 84: 1487–91.

    PubMed  Google Scholar 

  11. Ohnishi L, Lin KM, Chu TM. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Cancer Res 1990; 50: 1107–12.

    PubMed  Google Scholar 

  12. Kato K, Yamada T, Kawahara K, Onda H, Asano T, Sugino H, Kakinuma A. Purification and characterization of recombinant human interleukin-2 produced inEscherichia coli. Biochem Biophys Res Commun 1985; 130: 692–9.

    PubMed  Google Scholar 

  13. Yamada T, Kato K, Kawahara K, Nishimura O. Separation of recombinant human interleukin-2 and methionyl interleukin-2 produced inEscherichia coli. Biochem Biophys Res Commun 1986; 135: 837–43.

    PubMed  Google Scholar 

  14. Gefter ML, Margulies DH, Scharff MD. A simple method of polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977; 3: 231–6.

    PubMed  Google Scholar 

  15. Moriya N, Kato K, Suzuki N, Yamada T, Nishimura O. An enzyme immunoassay for human interleukin-2. J Immunoassay 1987; 8: 131–43.

    PubMed  Google Scholar 

  16. Iwasa S, Konishi E, Kondo K, Suzuki T, Akaza H, Niijima T. Selective cytotoxicity of drug-monoclonal antibody conjugates against murine bladder tumor cells. Chem Pharm Bull 1987; 35: 1128–37.

    PubMed  Google Scholar 

  17. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. An improved colorimetric assay for interleukin 2. J Immunol Methods 1986; 93; 157–65.

    PubMed  Google Scholar 

  18. Kumagai K, Itoh K, Suzuki R, Hinuma S, Saito F. Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities. J Immunol 1982; 129: 388–94.

    PubMed  Google Scholar 

  19. Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O, Tsukamoto K. Suppression of pulmonary tumor metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells. Immunol 1987; 60: 173–9.

    PubMed  Google Scholar 

  20. Ootsu K, Gotoh K, Houkan T. Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophoshamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors. Cancer Immunol Immunother 1989; 30: 71–80.

    PubMed  Google Scholar 

  21. Holton III OD, Black CDV, Parker RJ, Covell DG, Barbet J, Sieber SM, Talley MJ, Weinstein JN. Biodistribution of monoclonal IgG1, F(ab′)2, and Fab′ in mice after intravenous injection. J Immunol 1987; 139: 3041–9.

    PubMed  Google Scholar 

  22. Frodin JE, Lefvert AK, Mellstedt H. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules. Cancer Res 1990; 50: 4866–71.

    PubMed  Google Scholar 

  23. Hnatowich DJ, Gionet M, Rusckowski M, Siebecker DA, Roche J, Shealy D, Mattis JA, Wilson J, McGann J, Hunter RE, Griffin T, Doherty PW. Pharmacokinetics of111In-labeled OC-125 antibody in cancer patients compared with the 19-9 antibody. Cancer Res 1987; 47: 6111–7.

    PubMed  Google Scholar 

  24. Satoh J. Pharmacokinetics of an immune complex of rIL-2 and an antibody against rIL-2. Submitted for publication.

  25. Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res 1985; 45: 2421–4.

    PubMed  Google Scholar 

  26. Galvani DW, Walton S, Davies JM, Owen RR, Carr R, Cawley JC, Sells RA. Endolymphatic delivery of IL2 in patients with melanoma and lymphoma. Biotherapy 1992; 4: 251–5.

    PubMed  Google Scholar 

  27. Naruo K, Hinuma S, Kato K, Koyama M, Tada H, Shiho O, Tsukamoto K. Comparison of the biological properties of purified natural and recombinant human interleukin-2. Biochem Biophys Res Commun 1985; 128: 257–63.

    PubMed  Google Scholar 

  28. Hinuma S, Naruo K, Shiho O, Tsukamoto K. Characteristics of murine non-specific killer cells inducedin vivo by recombinant human interleukin-2, Immunol 1986; 59: 251–9.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. DDS Research Laboratories, Takeda Chemical Industries, LTD, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, 532, Osaka, Japan

    Jun Sato, Naoru Hamaguchi, Kazuhiro Doken, Susumu Iwasa, Yasuaki Ogawa & Hajime Toguchi

  2. Pharmaceutical Research Laboratories III, Pharmaceutical Research Division, Takeda Chemical Industries, LTD, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, 532, Osaka, Japan

    Kazunori Gotoh & Koichiro Ootsu

Authors
  1. Jun Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoru Hamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Doken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazunori Gotoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koichiro Ootsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Susumu Iwasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuaki Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hajime Toguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sato, J., Hamaguchi, N., Doken, K. et al. Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy 6, 225–231 (1993). https://doi.org/10.1007/BF01878084

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01878084

Key words

Search

Navigation